Biogen shares are trading lower amid a Friday increase in share price after the FDA voted in support of the company's Alzheimer's treatment.
Portfolio Pulse from Benzinga Newsdesk
Biogen shares are trading lower despite the FDA's support for the company's Alzheimer's treatment, following a Friday increase in share price.

June 12, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen shares trade lower despite FDA support for Alzheimer's treatment, following a Friday share price increase.
Biogen shares are trading lower despite the positive news of FDA support for their Alzheimer's treatment. This is likely due to profit-taking after the Friday increase in share price, which may have led to an overvaluation of the stock. In the short term, the stock price is likely to go down as investors adjust their positions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100